Financial Disclosure: Dr Reynolds has received pharmaceutical supplies for his National Institutes of Health–sponsored work from Forest Laboratories, Pfizer/Eisai, Bristol-Myers Squibb, Wyeth, and Eli Lilly and Co. Dr Butters has received remuneration from Northstar Neuroscience and Medtronic for services provided to clinical trials. Dr Lopez consults for Bristol-Myers Squibb and Pfizer/Eisai. Dr Pollock receives research support from the Sandra A. Rotman Program and Chair, the National Institutes of Health, and the Canadian Institutes of Health Research; within the past 5 years he has been a member of the advisory boards of Lundbeck Canada and Forest Laboratories; he has served 1 time as a consultant for Takeda and Wyeth; and he is currently a faculty member of the Lundbeck International Neuroscience Foundation. Dr Mulsant currently receives research support from the National Institutes of Health, the Canadian Institutes of Health Research, Bristol-Myers Squibb (pharmaceutical supplies), and Wyeth (pharmaceutical supplies); within the past 5 years he has received pharmaceutical supplies from Eli Lilly and Co and Pfizer; he has received honoraria for consulting or giving talks from AstraZeneca, Bristol-Myers Squibb, Forest Laboratories, and Pfizer; and he used to own stock (<$10 000) in Akzo-Nobel, Alkermes, AstraZeneca, Biogen, Celsion, Elan, Eli Lilly and Co, Forest Laboratories, Orchestra Therapeutics, and Pfizer. Dr Lenze has received research support from Forest Laboratories, Wyeth, Bristol-Myers Squibb, Pfizer, Novartis, and Ortho-McNeil Neurologics. Dr Mazumdar has stock ownership in Forest Laboratories. Dr Karp receives medication supplies from Eli Lilly and Co for investigator-initiated research. Dr Whyte has received investigator-initiated grants from Pfizer, Forest Laboratories, Ortho-McNeil, and Eli Lilly and Co. Dr Kaufer serves or has served as a consultant advisor to Accera, Cerebrio, Johnson & Johnson, Medivation, Novartis, Pfizer, Sanofi-aventis, and Solway Pharmaceuticals; has received speaking honoraria from Forest Laboratories, Eisai, Johnson & Johnson, Novartis, and Pfizer; and receives or has received research support from grants R01 AG022462, R21AG033387, K01 EB009724, and R49CE001495 from the National Institutes of Health, the Forest Research Institute, the Janssen Research Institute, Eisai/Pfizer, the Duke Endowment, the Guardian Angel Thrift Fund, the North Carolina Translational Research Center, and the US Administration on Aging. Dr DeKosky has received grants or research support in the past 5 years from Elan, Myriad, Neurochem, and GlaxoSmithKline and has served on the advisory boards or consulted for AstraZeneca, Abbott, Baxter, Daichi, Psychogenics, Myriad, Servier, and Wyeth.